Compare Cassava Sciences Inc (FLNA) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Otis Worldwide Corp — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Otis Worldwide Corp trades at $74.6 (market cap $27.70B). The key difference: Otis Worldwide Corp is far larger — about 521.3× Cassava Sciences Inc's market cap, and Otis Worldwide Corp pays a 2.35% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | OTIS | |
|---|---|---|
Market Cap | $53.14M | $27.70B |
Sector | Health | Industrials |
52-Week High | $4.64 | $101.07 |
52-Week Low | $1.09 | $69.34 |
Enterprise Value | -$33.43M | $35.09B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Otis Worldwide (OTIS) trades at $74.47, up 2.63% on the day, with a bearish technical signal and mixed earnings performance. The stock shows stable revenue near $14.4B but recent EPS misses in Q1 2026. Valuation metrics include a P/E of 19.2 and P/S of 1.93, while cash flow trends indicate net outflows. Recent news highlights modernization projects and a 5% dividend increase to $0.44 per share.
Outlook is cautious with analyst consensus at Buy (38%) and a $91 price target, but risks include declining net income margin to 9.59% and high debt-to-asset ratio of 75.54%. Opportunities lie in service growth and strategic deployments, though China headwinds and margin pressures persist. Investors should weigh solid fundamentals against near-term earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
